An OHSU study finds about 79% of clinical trial participants with leber congenital amaurosis experienced measurable improvement after receiving experimental, CRISPR-based gene editing: “This [is] a blinding disease with no treatments ... an enormous burden on patients [due] to their vision loss,” says Mark Pennesi, M.D., Ph.D.

Calls to poison centers, including the Oregon Poison Center at OHSU, for illicit fentanyl exposures in kids younger than 6 increased from 10 cases in 2016 to 539 in 2023. Rob Hendrickson, M.D., says: "It is imperative that the community provides resources to end the fentanyl epidemic and that people who use illicit drugs secure them from children by using opaque child-resistant lockable containers. We are extremely concerned about what we are seeing in the community and will continue to bring the issue to the forefront to raise awareness about how to prevent unintentional exposures among children."

In a The New York Times article about a new variant called KP.2, Fikadu Taffese, Ph.D., says researchers are still trying to determine to what degree repeat infections raise the risk of developing long COVID, as the pandemic continues to evolve. “That’s the nature of the virus. It keeps mutating," Tafesse says.

KGW-TV profiles Lorna Day and The Sam Day Foundation, which she created to honor her son's memory and advance childhood cancer research. The foundation is holding their annual Buddy Run on Saturday, May 18, at Doernbecher Children's Hospital.

The Columbia Memorial Hospital-Oregon Health & Science University Health Urology Clinic now offers men with prostate cancer targeted positron emission tomography imaging with Pylarify, an imaging agent approved by the Food and Drug Administration to identify suspected metastasis or a return of prostate cancer.

In a podcast interview with OncLive On Air, Shivaani Kummar, M.D., discusses the ongoing investigation of the first-in-class p53 therapy rezatapopt for patients with mutated advanced solid tumors. Kummar says: “I’ve been doing drug development for over 20 years, and I find that this point is one of the most exciting times in this field as we now have the ability to specifically design molecules against molecular targets within cancer cells as well as a slew of different types of agents that target the tumor microenvironment and the immune cells.”

An OHSU study finds about 79% of clinical trial participants with leber congenital amaurosis experienced measurable improvement after receiving experimental, CRISPR-based gene editing: “This [is] a blinding disease with no treatments ... an enormous burden on patients [due] to their vision loss,” says Mark Pennesi, M.D., Ph.D.

OHSU study finds combined cannabis and nicotine use during pregnancy is associated with significantly higher risk of poor health outcomes for newborns compared with use of either substance alone.

OHSU study finds combined cannabis and nicotine use during pregnancy is associated with significantly higher risk of poor health outcomes for newborns compared with use of either substance alone.

As the FDA considers a requirement for blood banks to use a new test that can detect the parasites that cause malaria in certain donors’ blood, an advisory committee favors selective testing based on certain criteria over testing all donors: “It’s such a low incidence of disease, and it’s treatable,” said Richard Scanlan, M.D.